Instrument Inactif

Communiqués Merrion Pharmaceuticals Plc

Actions

3MP

IE00B282VY28

Produits pharmaceutiques

Communiqués

26/08/16	Merrion Pharmaceuticals : Notice of General meetings	PU
23/08/16	Merrion Pharmaceuticals : Proposed liquidation	PU
17/12/15	Merrion Pharmaceuticals : Disposal Completion	PU
01/10/15	Merrion Pharmaceuticals : Interim results for the six month period ended 30 June 2015, Dublin, Ireland 30 September 2015	PU
02/09/15	Merrion Pharmaceuticals : Announces Continuing Progress of Oral Insulin Projects Using Merrion Pharmaceuticals' GIPET Technology under license to its partner Novo Nordisk A/S	PU
18/08/15	Merrion Pharmaceuticals : Annual Report and Notice of AGM	PU
01/07/15	Merrion Pharmaceuticals : Annual Report	PU
15/01/15	Merrion Pharmaceuticals : Announces Completion of Disposal of Citywest Facility	PU
18/12/14	Merrion Pharmaceuticals : "Merrion" or the "Company") announces the proposed disposal of its Citywest facility for a consideration of €2,175,000	PU
04/09/14	Merrion Pharmaceuticals : Receives Milestone Payment Following Successful Completion of a Phase I Study of Novo Nordisk A/S Oral GLP-1 Analogue (NN9928) Using Merrion Pharmaceuticals' GIPET Technology	PU
15/07/14	Merrion Pharmaceuticals : Hovione and Merrion Pharmaceuticals Announce Strategic Partnership on Use of Merrion's GIPET Technology	PU
18/06/14	Merrion Pharmaceuticals : Annual Report and Notice of AGM and EGM	PU
18/06/14	Merrion Pharmaceuticals : Directorate Change	PU
30/05/14	Merrion Pharmaceuticals' : GIPET Technology Progresses with Novo Nordisk Oral Insulin Development	PU
11/04/14	Merrion Pharmaceuticals : FDA meeting clears way for MER-101 in treatment of early breast cancer	PU
07/03/14	Merrion Pharmaceuticals Plc : Novo Nordisk A/S Successfully Completes Phase I Trial of its Proprietary Oral Insulin (NN1956) using Merrion Pharmaceuticals' GIPET® Technology.	PU
23/12/13	Merrion Pharmaceuticals Plc : Appointment of Director	PU
23/12/13	Merrion Pharmaceuticals Plc : Appointment of CEO and Chairman	PU
30/09/13	Merrion Pharmaceuticals Plc : Interim Results for the Six Months Ended 30 June 2013	PU
18/09/13	Merrion Pharmaceuticals Plc : Result of AGM	PU
20/08/13	Merrion Pharmaceuticals Plc : Appointment of Non-Executive Director	PU
11/06/13	Merrion Pharmaceuticals Plc : Grant of Options	PU
10/06/13	Merrion Pharmaceuticals Plc : Annual Report	PU
20/03/13	Merrion Pharmaceuticals Plc : Novo Nordisk A/S Successfully Completes Phase I Trial of its Proprietary Oral Insulin (NN1954) Using Merrion Pharmaceuticals GIPET® Technology	PU
02/01/13	Merrion Pharmaceuticals Plc : Grant of Shares and Options	PU